All Stories

  1. Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy
  2. Raised circulating Neurokinin A predicts prognosis in metastatic small bowel neuroendocrine tumours. Lowering Neurokinin A indicates improved prognosis
  3. Biochemical markers of placental dysfunction in assisted conception
  4. Response to interferon alpha Ardill
  5. The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional Study
  6. Raised neurokinin A (NKA) is a good predictor of prognosis in metastatic neuroendocrine tumours of the midgut and lowering NKA by treatment improves prognosis significantly. A retrospective study 1989–2011
  7. Validation of Neurokinin A Assays in the United States and Europe
  8. Circulating Biomarkers in Neuroendocrine Tumors of the Enteropancreatic Tract: Application to Diagnosis, Monitoring Disease, and as Prognostic Indicators
  9. Audit of the prescription of antipsychotic medication in patients with neuroendocrine tumours (NETs) with terminal disease
  10. Comparison of three commercial methods for chromogranin A measurement
  11. Higher plasma leptin, after body mass index adjustment, in women with delayed pregnancy
  12. Difficulty of diagnosis of gastrinoma with gastrin assay
  13. Neurokinin A is a sensitive marker and excellent prognostic indicator for serotonin secreting tumours of the ileum and colon
  14. Regional laboratory audit to evaluate specificity and sensitivity of chromogranin A and peptide markers for neuroendocrine tumours
  15. Neuroendocrine tumours of the small bowel ardill
  16. Circulating markers for endocrine tumours of the gastroenteropancreatic tract
  17. Cox-2 Promotes Chromogranin A Expression and Bioactivity: Evidence for a Prostaglandin E2-Dependent Mechanism and the Involvement of a Proximal Cyclic Adenosine 5′-Monophosphate-Responsive Element
  18. Increased tachykinin levels in induced sputum from asthmatic and cough patients with acid reflux
  19. The effect of H2-blockade on plasma gastrin concentration in patients with an achlorhydric stomach
  20. Effect of omeprazole and feeding on plasma gastrin in patients with achlorhydria
  21. Calcitonin gene-related peptide relates to cough sensitivity in children with chronic cough
  22. An Evaluation of Cyclooxygenase-2 as a Prognostic Biomarker in Mid-Gut Carcinoid Tumours
  23. Vasoactive intestinal polypeptide (VIP) and VPAC1 receptor in adult human dental pulp in relation to caries
  24. Plasma concentrations of glucagon-like peptide-2 in adult patients with treated and untreated coeliac disease
  25. Reply
  26. Endobronchial adenosine monophosphate challenge causes tachykinin release in the human airway
  27. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop
  28. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut
  29. Gastrin: an analytical review
  30. Distribution of Glucagon-Like Peptide-2 in Normal Colonic Tissue
  31. Variations in serum vascular endothelial growth factor binding profiles and the development of ovarian hyperstimulation syndrome
  32. Changes in vasoactive intestinal peptide in gingival crevicular fluid in response to periodontal treatment
  33. Gastrin, somatostatin and infantile hypertrophic pyloric stenosis
  34. Gastrin, somatostatin and infantile hypertrophic pyloric stenosis
  35. Gastrin, somatostatin and infantile hypertrophic pyloric stenosis
  36. Plasma neurokinin a concentrations accurately predict poor prognosis in patients with midgut carcinoid tumors
  37. Plasma neurokinin a concentrations accurately predict poor prognosis in patients with midgut carcinoid tumors
  38. Distribution of glucagon-like peptide-2 (GLP-2) in normal colonic tissue
  39. Gastric corpus atrophy following eradication of Helicobacter pylori
  40. Distribution of glucagon-like peptide-2 (GLP-2) in normal colonic tissue
  41. Molecular forms of gastrin in the circulation of patients with achlorhydria
  42. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole
  43. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status
  44. Autoantibodies to gastrin in patients with pernicious anaemia--a novel antibody
  45. Gastrinomas and the change in their presentation and management in Northern Ireland, UK, from 1970 to 1996
  46. Gastrin Somatostatin and Infantile Pyloric Stenosis
  47. Nitric oxide and gall-bladder motor function
  48. Neutralization by ammonia cannot explain H. pylori's potentiation of Omeprazole's efficacy
  49. Rebound acid hypersecretion post-omeprazole correlates with on-treatment intragastric pH and on-treatment plasma gastrin
  50. Prohormone convertases PC1/3 and PC2 are expressed in autoimmune atrophic gastritis
  51. Atrophic gastritis and Helicobacter pylori infection in patients treated with proton pump inhibitors
  52. Eradicating Helicobacter pylori reduces hypergastrinaemia during long term omeprazole treatment
  53. Eradicating Helicobacter pylori reduces hypergastrinaemia during long term omeprazole treatment
  54. The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori–infected healthy subjects
  55. Helicobacter pylori infection and chronic gastric acid hyposecretion
  56. Salmon calcitonin-like immunoreactivity in human neuroendocrine tumours
  57. Successful pregnancy in association with Zollinger-Ellison syndrome
  58. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease
  59. Age dependent hypergastrinaemia in children with Helicobacter pylori gastritis--evidence of early acquisition of infection.
  60. Pathogenesis of Diarrhoea in Medullary Thyroid Carcinoma
  61. A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of acid secretion as duodenal ulcer patients.
  62. Helicobacter pylori, hypergastrinaemia, and recurrent abdominal pain in children
  63. The effect of Helicobacter pylori on fasting plasma gastrin levles in children
  64. Circulating regulatory peptide levels in lung cancer
  65. Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumor resection
  66. Gastrin levels in Pernicious anaemia
  67. Antral gastrin cell counts in Helicobactor Pylori infected patients
  68. Immunohistochemistry of carcinoid tumours of the rectum
  69. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer.
  70. Helicobacter pylori related hypergastrinaemia is the result of a selective increase in gastrin 17.
  71. Changing patterns in the management of zollinger-ellison syndrome
  72. Elevated plasma levels of gastrin found in the presence of helicobacter pylori infection are predominantly due to the elevation of gastrin-17
  73. Various immunostaining patterns of gastrinomas
  74. Is pancreastatin (33–49) biologically active in vitro?
  75. The parietal cell is not the site for xenopsin mediated acid inhibition
  76. Xenopsin immunoreactivity in antral G-cells may reside in the N-terminus of gastrin 17
  77. Preparation and biological activity of N-tBOC-Trp-Leu-β-Ala: A C-terminal gastrin analogue
  78. Xenopsin immunoreactivity in G-cells resides in the N-terminus of gastrin-17
  79. Neuroendocrine tumors: A European view
  80. Absence of evidence for a role of calcitonin in the etiology of femoral neck fracture
  81. Transpulmonary Levels of Plasma Immunoreactive Calcitonin in Man
  82. Non Small Cell Lung Cancer and Elevated Plasma Immunoreactive Calcitonin
  83. Suppression of somatostatin release by duodenogastric reflux in dogs.
  84. Distribution of vasoactive intestinal polypeptide immunoreacticity (VIP-IR) on leucocytes
  85. The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects
  86. Eating, Energy Metabolism and Vasoactive Intestinal Peptide
  87. Vasoactive intestinal peptide (VIP) — Immunoreactive cells in the epithelium of mammalian intestine — Fact or fantasy?
  88. 2 Radioimmunoassay of GI hormones
  89. Entero-pancreatic hormones in migraine
  90. Effect of catecholamines on gastrin release
  91. Pathophysiology of gastrin and secretin.
  92. Increased Somatostatin Immunoreactive Cells in the Islets of Streptozotocin Treated Rats Rats
  93. Gastrin levels after proximal gastric vagotomy
  94. Neonatal gastric hyperacidity: further analysis of oxytocin effect.
  95. Gastrin and insulin release
  96. Neonatal secretion of gastrin and glucagon
  97. A duodenal role in gastrin release
  98. Plasma Gastrin Responses to Arginine in Chronic Pancreatitis
  99. Gastrin and Duodenal Ulceration
  100. Hypergastrinaemia in rheumatoid arthritis: disease or iatrogenesis.
  101. The acute effect of tetracosactrin on carbohydrate, insulin, glucagon, gastrin and lipid metabolism in rheumatoid arthritis
  102. STIMULATION OF GASTRIN RELEASE BY CATECHOLAMINES